Alcobra Ltd. (NASDAQ:ADHD)’s share price fell 3.2% during trading on Thursday . The company traded as low as $4.76 and last traded at $4.84, with a volume of 72,278 shares. The stock had previously closed at $5.00.

A number of research firms have commented on ADHD. Zacks Investment Research raised shares of Alcobra from a “sell” rating to a “hold” rating in a research note on Tuesday, July 26th. Canaccord Genuity began coverage on shares of Alcobra in a research note on Tuesday, June 7th. They issued a “buy” rating for the company. Roth Capital reissued a “buy” rating and issued a $12.00 price target on shares of Alcobra in a research note on Tuesday, June 21st. Barclays PLC began coverage on shares of Alcobra in a research note on Monday. They issued an “equal weight” rating and a $8.00 price target for the company. Finally, Cantor Fitzgerald began coverage on shares of Alcobra in a research note on Tuesday, June 7th. They issued a “buy” rating and a $16.00 price target for the company. Three analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average target price of $10.25.

The stock’s 50 day moving average price is $4.37 and its 200 day moving average price is $4.57. The firm’s market capitalization is $133.40 million.

Alcobra (NASDAQ:ADHD) last posted its quarterly earnings data on Monday, May 16th. The company reported ($0.18) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.04. Equities analysts forecast that Alcobra Ltd. will post ($0.97) earnings per share for the current fiscal year.

Alcobra Ltd is an Israel-based Biopharmaceutical company. It focuses on the development and commercialization of a proprietary drug, MG01CI, to treat Attention Deficit Hyperactivity Disorder (ADHD), a common and morbid neuropsychiatric condition in children and adults. Adult ADHD is associated with increased health risks and healthcare costs, higher divorce rates, lower levels of socioeconomic attainment, lower academic achievement, unemployment and work place deficits, increased risks for motor vehicle accidents, greater likelihood of additional psychiatric disorders, increased criminal activity and incarceration, and higher rates of substance use and abuse.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.